Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06587828
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-04-18
Brief Title:
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation These tissues contain both cytotoxic and helper T cells that are driving their disease and these T cells are being guided by TCRs that recognize tissue-specific targets By collecting tissue when a patient has active inflammation it is possible to determine which T cells are activated and undergoing clonal expansion in the patients diseased organ TScan has developed a genome-wide high-throughput technology to determine the natural physiological target of any TCR Kula 2019 The goal of this study is to isolate T cells from inflamed tissues and matched blood samples andor matched normal tissues for patients with inflammatory bowel diseases T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScans genome-wide high-throughput target ID technology
The goal of this study is to discover a collection of peptide targets along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases
The goal of this study is to discover a collection of peptide targets along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None